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Letter to the Editor
Acquired Hemoglobin C Secondary to Transfusion With
Antigen-Matched Red Blood Cells
David P. Arps, Donald A. Giacherio, and Laura L. Cooling*
Department of Pathology, University of Michigan, Ann Arbor, Michigan
To the Editor:
Raciti et al. [1] recently described a patient with
sickle cell disease requiring chronic transfusion sup-
port, who was passively transfused with hemoglobin C
(HgbC), hemoglobin G-Philadelphia, and glucose-6-
phosphate dehydrogenase deficient RBC units all of
which were antigen-matched to reduce the likelihood
of alloimmunization. We would like to share our expe-
rience with a similar patient.
The patient was a 13-year-old black male with
sickle cell disease complicated by pain crises, priapism,
silent brain infarcts, iron overload, and alloimmuniza-
tion (anti-E), who receives simple blood transfusion
every three weeks. Per institutional policy, the patient
receives units matched for Rh and K1 antigens, with
extended matching for Fya and S, if possible.
Most recently, the patient was transfused with two
antigen-matched, crossmatch-compatible RBC units
(A-positive; E-, K1-, S-, Fya-) without incident and an
appropriate post-transfusion increase in hemoglobin
(pre: 8.2 g/dL, post: 9.6 g/dL). A post-transfusion
hemoglobin fractionation and quantification was per-
formed using high-performance liquid chromatography
(HPLC, Bio-Rad Variant II System; Hercules, CA).
The patient had the expected reduction in HgbS
(18.8%); however, there was a new minor peak (5.05
minutes, 2.2% total) eluting in the “C-window,” con-
sistent with HgbC (Fig. 1A). This was confirmed
by capillary zone electrophoresis (Sebia Capillarys,
Fig. 1C). Sample contamination was excluded and a
review of the patient’s previous hemoglobin evalua-
tions confirmed this was a new peak.
Because of the recent transfusion, retained segments
from the two RBC units were subjected to HPLC anal-
ysis. The first unit demonstrated a normal chromato-
gram, while the second unit (Fig. 1B) disclosed a peak
eluting at 5.16 min comprising 31.4% of the total
hemoglobin, consistent with a HgbC heterozygous
donor. The slightly later elution time seen in the donor
(5.16 versus 5.05 min) is an artifact of the HPLC
method whereby smaller peaks tend to elute slightly
faster than large peaks. This artifact was confirmed
with a titration study performed by the authors.
As mentioned by Raciti et al. [1], we too considered
the consequences of antigen-matching for this patient.
Donors negative for K1, S, and Fya antigens are signif-
icantly more common among black donors (60% versus
15% white) [2], thus increasing the likelihood of trans-
fusion with HgbC. HgbC is present in 2.4% of African
Americans and is particularly high among those of
west Africa descent, where the incidence of HgbC
reaches 25% of the general population [3]. Less com-
monly, HgbC may be seen in those of Middle Eastern
and Mediterranean descent [4]. Interestingly, the donor
in our case was a 62-year-old Caucasian female who
was a long-time donor.
Clinically, individuals with HgbC trait are asymp-
tomatic. Passive transfusion of donor RBC with HgbC
trait is unlikely to adversely affect transfusion efficacy
although it can confuse diagnostic testing. There are
also ethical issues regarding the need to inform the
donor. While HgbC trait is a benign disorder, homo-
zygosity (HgbC disease) or inheritance with another
hemoglobin variant such as HgbS (Hgb SC disease)
can lead to a clinically relevant hemoglobinopathy
with implications for genetic counseling.
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Fig. 1. Panel (A) is the patient’s post-transfusion chromatogram
demonstrating hemoglobins F, A1, A2, S, and a small amount of
hemoglobin C (2.2%) eluting at 5.05 min. Panel (B) is the chromat-
ogram of the donor unit demonstrating heterozygosity for hemoglo-
bin C which elutes at 5.16 min, slightly later than seen in Panel
(A). Panel (C) is the confirmatory capillary zone electrophoresis
chromatogram of the patient’s post-transfusion sample, demonstrat-
ing a small peak corresponding to hemoglobin C (1.9%).
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